Arthur Rosenthal
Description Dr. Rosenthal was appointed to our Board in January 2007. In June 2009, he was appointed President and CEO of Cappella, Inc., a development stage company focused on novel device solutions for coronary artery disease. He served as Chairman commencing in January 2002, and CEO commencing in January 2005, of Labcoat, Ltd. until its acquisition by Boston Scientific Corporation in December 2008. From January 1994 to May 2000, he was a Senior Vice President, Corporate Officer, and Chief Development Officer of Boston Scientific, and from May 2000 until his retirement in January 2005, he was a Senior Vice President, Chief Scientific Officer, and Executive Committee Member of Boston Scientific. Dr. Rosenthal retired in February 2010 from his position as a non-executive director and Chairman of the Remuneration Committee for Renovo, Ltd., a U.K. publicly-traded pharmaceutical company. In July 2009, Dr. Rosenthal joined the board of Interface Biologics, Inc, a Toronto-based development stage company focused on drug delivery devices, as a non-executive director. Dr. Rosenthal?s particular qualifications for service on our Board include his extensive knowledge of regulatory and compliance requirements pertaining to medical devices, his experience with new product development, and his experience as an operating executive at a major medical device manufacturer. To view the detailed information, you need to SUBSCRIBE with us. |
 |